A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing blockbuster. The US District Court for the Northern District of West ...

Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1 billion of that coming from the US market, where an authorised generic sold under license from AZ has been available since ...

Wealthfront Advisers LLC acquired a new stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange ...

Lynparza and Symbicort, beating estimates. The British drugmaker said that the impact of the ongoing investigations in China remains minor on the business. In December, AstraZeneca appointed Iskra ...

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...

AstraZeneca has built its leading presence ... with growth in Breztri and Tezspire offsetting declines in Symbicort. We have strong growth expectations for recently launched drugs Enhertu (HER2 ...

We recently published a list of 10 Best European Stocks to Buy According to Billionaires. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best ...

Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.' ...

AstraZeneca’s diverse portfolio includes leading products such as Tagrisso, Imfinzi, and Lynparza in oncology and Symbicort in respiratory care. AZN is among the best European stocks according ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...

The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...